tirzepatide surmount 2 Semaglutide vs. for Obesity SURMOUNT-1 Trial - Cardionerds Twitter

PlexusDx patients taking tirzepatide injection need a deliberate hydration strategy to maximize results and minimize discomfort

The entire gastrointestinal tract moves more sluggishly during GLP-1 therapy

Vomiting and Diarrhea : Along with nausea, some people experience vomiting and diarrhea

Although DSM-5 diagnosis is defined through multiple behavioral criteria encompassing impaired control, social dysfunction, continued use despite harm, and tolerance or withdrawal, converging clinical and preclinical evidence indicates that the core pathological feature of SUDs is the progressive loss of control over intake (O'Brien, 2005)

Recent Major Changes Indications and Usage for Vyvanse VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of (1): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use: The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage (5.5, 8.4) VYVANSE is not indicated for weight loss